About Us : Faculty : Naliboff
Click to view Biographical Sketch
Bruce D. Naliboff, Ph.D.
Clinical Professor, Department of Psychiatry and Biobehavioral Sciences, at the
David Geffen School of Medicine, UCLA
Co-Director, UCLA Center for Integrative Medicine
Director, Human Physiological Reserach, CNS: Center for Neurovisceral Sciences and Women's Health, UCLA Division of Digestive Diseases
Chief, Psychophysiology Research Laboratory, VA Greater Los Angeles Healthcare System
Senior Research Scientist, Cousins Center for Psychoneuroimmunology, UCLA Neuropsychiatric Institute

Research Interests

Dr. Naliboff’s research has focused on psychophysiological mechanisms of stress and pain. Past studies have addressed how stress impacts the immune system, glucose regulation in diabetes, and cardiovascular variables. He has also studied psychosocial and personality variables in chronic pain and especially their impact on treatment choice and outcome.

Dr. Naliboff conducts etiologic and treatment studies of functional gastrointestinal disorders such as Irritable Bowel Syndrome (IBS). These include perceptual, autonomic, and brain imaging studies of visceral sensation, and the role of psychosocial variables in the presentation, course and treatment of IBS. A major emphasis of his current work is the relationship between central stress mechanisms and both somatic and visceral pain disorders. Another area of interest is in the relationship between anxiety and symptoms in chronic pain disorders. Dr. Naliboff has NIH funding to study gender differences in central responses to visceral sensation as well as the role of visceral specific anxiety in Irritable Bowel Syndrome. He has recently begun a clinical trial comparing several psychological treatments for IBS and has an ongoing clinical trial of opioid medications in of chronic pain. He collaborates with other UCLA investigators on studies of neuroendocrine and immune factors in pain conditions such as IBS and fibromyalgia.

Current research

Health Outcomes from Opiate Therapy for Chronic Pain
Primary Investigator: Naliboff
Agency: VA/HSRD
Type: IIR-98149-2 Period: 10/01/00-09/30/04
The major goals of this project are: 1) Compare two distinct clinical guidelines for management of chronic pain with narcotic medications over a 12-month period; 2) Examine medical and psychological predictors of treatment outcome, addiction potential, and healthcare use in patients treated with chronic opiate therapy.

Treatment of Pain and Fear in Irritable Bowel Syndrome
Principal Investigator: Naliboff
Agency: NIH/NINR Period: 7/01/02-06/30/07
Type: NR007768
The major goals of this randomized clinical trial are: 1) To compare symptom and Quality of Life responses in IBS patients to three treatment conditions: a novel behavioral treatment using exposure and directed attention, a stress management treatment, and an educational intervention. 2) To compare the treatments on visceral sensitivity, hypervigilance and autonomic responses, and 3) To compare the treatments on central responses to visceral related stimuli using functional brain imaging.

Recent publications

Naliboff BD, Solomon GF, Gilmore S, Benton D, Fahey JL, Pine J. Rapid changes in cellular immunity following a confrontational role-play stressor. Brain Behavior and Immunity 9: 207-219, 1995.

Lembo A, Naliboff BD, Matin K, Munakata J, Parker R, Gracely R, Mayer EA. Irritable bowel syndrome patients show altered sensitivity to exogenous opioid. Pain, 1195-1200, 2000.

Naliboff BD, Derbyshire SWG, Munakata J, Berman S, Mandelkern M, Chang L, Mayer EA. Cerebral activation in irritable bowel syndrome patients and control subjects during rectosigmoid distension. Psychosomatic Medicine, 63: 365-375, 2001.

Cole SW, Naliboff BD, Kemeny ME, Griswold M, Fahey JL, & Zack JA. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity . PNAS USA, 98, 12695-12700, 2001.

Chang L, Munakata J, Naliboff B, Saba L, Matin K, Bernstein C, Anton PA, Mayer EA. Perceptual responses in patients with inflammatory and functional bowel disease. Gut, 47:497-505, 2000.

Bruce D. Naliboff, Ph.D.
CNS: Center for Neurovisceral Sciences and Women's Health
CURE Building, 115 Room 223
11301 Wilshire Boulevard
Los Angeles, CA 90073
Tel: (310) 268-3242
Fax: (310) 794-2864
Web: www.ibs.med.ucla.edu, www.uclamindbody.org